At a glance
- Originator AstraZeneca
- Class Heart failure therapies; Small molecules; Vasodilators
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Heart failure
Most Recent Events
- 06 Sep 2000 Discontinued-Preclinical for Heart failure in United Kingdom (Unknown route)
- 07 Apr 1999 Merger of Zeneca and Astra to form AstraZeneca completed